BioCentury | Dec 17, 2012
Emerging Company Profile

Haplogen: Mining for host factors

Haplogen GmbH is screening haploid human cells to identify new host factors required for bacterial or viral infection, which it hopes will lead to the development of anti-infectives with less potential for resistance. Haplogen was...
BC Week In Review | Jul 5, 2004
Clinical News

Tarceva erlotinib regulatory update

OSIP said its NDA for Tarceva to treat advanced or metastatic non-small cell lung cancer (NSCLC) was accepted into FDA's Pilot 1 Program for Continuous Marketing Applications (CMAs). The program allows for rolling submissions of...
Items per page:
1 - 2 of 2